Entera Bio Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, specializing in the oral delivery of large molecule therapeutics. The company leverages its proprietary N-Tab technology platform to protect and facilitate the absorption of peptides and proteins in the gastrointestinal tract, offering a needle-free alternative to traditional injectable biologic treatments. Entera's most advanced clinical programs include EB613, an oral formulation of human parathyroid hormone (PTH) for the treatment of postmenopausal women with osteoporosis, and EB612, an oral PTH replacement therapy for hypoparathyroidism. Additionally, the company is advancing early-stage programs targeting obesity and metabolic syndromes, including an oral GLP-1/glucagon peptide tablet. Entera operates primarily through a business-to-business model, seeking strategic partnerships and collaborations with pharmaceutical companies to advance its pipeline and commercialize its therapeutic candidates globally.
